Treating and Supporting Someone with PARK25
At a Glance
PARK25 care usually combines a carefully monitored levodopa trial for movement symptoms with physical, occupational, speech, educational, and cognitive support. Medicines should not be stopped abruptly, and deep brain stimulation is considered only in selected cases.
Managing PARK25 requires a dual approach that addresses both the physical movement symptoms and the lifelong cognitive needs. While there is currently no cure that fixes the underlying gene mutation, the symptoms themselves are often responsive to medical treatments [1].
The Mainstay of Treatment: Levodopa
A significant finding in the few reported families with PARK25 is a response to a carefully monitored trial of levodopa (often prescribed as Carbidopa-Levodopa) [1]. This medication provides the brain with the dopamine it struggles to regulate.
- Motor Improvement: Some reported patients have seen improvements in their ability to walk and move after starting levodopa [1].
- Dosage and Timing: Doses in reported historical cases have ranged from 250 mg to 500 mg per day [1], but this is case-report data, not a recommended target dose. Formulation, age, weight, and schedule must be determined by a specialist. Doctors often split these into multiple doses throughout the day to keep levels steady [2]. Readers must never adjust, double, or stop doses without prescriber instructions.
- Adverse Effects: In young patients, a common complication of levodopa is dyskinesia [1]. These are involuntary, jerky, or “dance-like” movements. In some cases of PARK25, these dyskinesias have been described as appearing early and severely [1]. Other clinically important adverse effects include nausea, dizziness/orthostatic hypotension, sleepiness, hallucinations, and confusion [3].
Safety Box: Avoiding Abrupt Withdrawal
It is vital to never stop or abruptly interrupt Parkinson’s medications. Doing so can lead to a dangerous emergency called Parkinsonism-Hyperpyrexia Syndrome (PHS) [4].
- PHS is associated with abrupt withdrawal or prolonged interruption of dopaminergic therapy (not a single missed dose).
- Emergency features include high fever, severe rigidity, altered mental status, and autonomic instability.
- Families must seek emergency care if this occurs, and establish a written sick-day/surgery plan for situations involving vomiting or inability to take oral medications.
Advanced Options: Deep Brain Stimulation (DBS)
For individuals whose motor symptoms progress or who develop severe side effects from medication, Subthalamic-nucleus deep-brain stimulation (STN-DBS) may be considered. DBS involves a surgical procedure to place thin wires in the brain that deliver mild electrical pulses [1].
In very limited case reports of PARK25, DBS was reported to be effective [1]. However, DBS is an exceptional, individualized option after specialist assessment, with no established PARK25-specific eligibility criteria. Risks include surgical complications, infection, hemorrhage, and effects on speech, mood, or cognition. Consent and communication considerations for someone with intellectual disability must be carefully weighed by the team [5][6].
Supportive Care for Intellectual Disability
Because the cognitive symptoms of PARK25 typically remain stable, the focus is on maximizing quality of life [1]. There is no specific drug for the intellectual disability aspect, so care is primarily supportive:
- Physical and Occupational Therapy (PT/OT): Essential for maintaining muscle flexibility, improving balance, and adapting the home environment [7].
- Speech and Swallowing Therapy: Important for monitoring any changes in the ability to speak clearly or swallow safely [8].
- Educational Support: Individualized Education Programs (IEPs) or vocational training tailored to specific learning styles [9].
- Neuropsychological Care: Regular check-ins to monitor cognitive health and provide behavioral strategies [10].
Common questions in this guide
Can levodopa improve movement symptoms in PARK25?
What should we do if involuntary movements begin after levodopa?
Why should PARK25 medicines not be stopped suddenly?
Could deep brain stimulation help someone with PARK25?
What therapies support intellectual disability and daily function in PARK25?
Which side effects of levodopa should families watch for?
Get notified when new evidence is published on Parkinson disease 25, autosomal recessive early-onset, with impaired intellectual development.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (10)
- 1
PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability.
Fevga C, Tesson C, Carreras Mascaro A, et al.
Brain : a journal of neurology 2023; (146(4)):1496-1510 doi:10.1093/brain/awac326.
PMID: 36073231 - 2
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
Vijayakumar D, Jankovic J
Drugs 2016; (76(7)):759-77 doi:10.1007/s40265-016-0566-3.
PMID: 27091215 - 3
Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
Tran TN, Vo TNN, Frei K, Truong DD
Journal of neural transmission (Vienna, Austria : 1996) 2018; (125(8)):1109-1117 doi:10.1007/s00702-018-1900-6.
PMID: 29971495 - 4
Whether to Proceed With Deep Brain Stimulator Battery Change in a Patient With Signs of Potential Sepsis and Parkinson Hyperpyrexia Syndrome: A Case Report.
Liu CJ, Crnkovic A, Dalfino J, Singh LY
A & A case reports 2017; (8(8)):187-191 doi:10.1213/XAA.0000000000000462.
PMID: 28166109 - 5
Assessment of individual cognitive changes after deep brain stimulation surgery in Parkinson's disease using the Neuropsychological Test Battery Vienna short version.
Foki T, Hitzl D, Pirker W, et al.
Wiener klinische Wochenschrift 2017; (129(15-16)):564-571 doi:10.1007/s00508-017-1169-z.
PMID: 28176003 - 6
Short and Long-Term Cognitive Effects of Subthalamic Deep Brain Stimulation in Parkinson's Disease and Identification of Relevant Factors.
Jahanshahi M, Leimbach F, Rawji V
Journal of Parkinson's disease 2022; (12(7)):2191-2209 doi:10.3233/JPD-223446.
PMID: 36155529 - 7
Pediatric parkinsonism: clinical review and a proposed clinical algorithm.
Naranjo-Lobo V, Hidalgo-Bravo MJ, Munoz-Chesta D, Troncoso-Schifferli M
Frontiers in neurology 2026; (17()):1788936 doi:10.3389/fneur.2026.1788936.
PMID: 42483444 - 8
Combined molecular characterization and dopa-responsive treatment in two patients with NR4A2-associated intellectual developmental disorder.
Liang N, Li T, Deng Y
Frontiers in genetics 2025; (16()):1590292 doi:10.3389/fgene.2025.1590292.
PMID: 41019763 - 9
A review of cognitive impairments in children with intellectual disabilities: Implications for cognitive behaviour therapy.
Hronis A, Roberts L, Kneebone II
The British journal of clinical psychology 2017; (56(2)):189-207 doi:10.1111/bjc.12133.
PMID: 28397306 - 10
Pediatric-Onset Epilepsy and Developmental Epileptic Encephalopathies Followed by Early-Onset Parkinsonism.
Spagnoli C, Fusco C, Pisani F
International journal of molecular sciences 2023; (24(4)) doi:10.3390/ijms24043796.
PMID: 36835207
This page is for informational purposes only and does not constitute medical advice. A movement-disorders specialist and the patient’s care team should guide levodopa use, emergency medication plans, deep brain stimulation decisions, and supportive therapies.